產品詳情
簡單介紹：
Anti-Rarres3抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-Rarres3抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-Rarres3
Cat. Number:
Anti-Rarres3抗體KL-1917R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Retinoids exert biologic effects such as potent growth inhibitory and cell differentiation activities and are used in the treatment of Anti-Rarres3抗體hyperproliferative dermatological diseases. These effects are mediated by specific nuclear receptor proteins that are members of the steroid and thyroid hormone receptor superfamily of transcriptional regulators. RARRES1, RARRES2, and RARRES3 are genes whose expression is upregulated by the synthetic retinoid tazarotene. RARRES3 is thought act as a tumor suppressor or growth regulator. [provided by RefSeq, Jul 2008].
Also known as:
Retinoic acid receptor responder protein 3;Anti-Rarres3抗體 HRASLS4; MGC8906; RAR responsive protein TIG3; Retinic acid inducible gene 1; Retinoic acid receptor responder (tazarotene induced) 3; Retinoid inducible gene 1 protein; RIG 1; rig1; Tazarotene induced gene 3 protein; TIG 3; TIG3; p18H-rev 107; Group XVI phospholipase A2; HRAS-like; rCG47447; HRSL4_HUMAN; HRAS-like suppressor 4; HRSL4; RAR-responsive protein TIG3; Retinoid-inducible gene 1 protein.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Anti-Rarres3抗體Protein A.
●
Reacts with: Human, Dog, Rabbit, .
●
Immunogen: KLH conjugated synthetic peptide derived from human Rarres3.
●
Predicted Molecular Weight: 18kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-Rarres3抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-Rarres3抗體
Optimal working dilutions must be determined by the end user.
